A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2014
At a glance
- Drugs Dolcanatide (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Synergy Pharmaceuticals Inc
- 24 Oct 2012 Planned number of patients changed to 56.
- 22 Oct 2012 New source identified and integrated (ClinicalTrials.gov).
- 19 Oct 2012 Status changed from planning to recruiting as reported in a Synergy Pharmaceuticals media release.